TY - JOUR
T1 - Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies
T2 - ISSCR 2018 Annual Meeting Focus Session Report
AU - Sugarman, Jeremy
AU - Barker, Roger A.
AU - Kerridge, Ian
AU - Lysaght, Tamra
AU - Pellegrini, Graziella
AU - Sipp, Douglas
AU - Tanner, Claire
N1 - Funding Information:
J.S. is a member of Merck KGaA's Bioethics Advisory Panel and Stem Cell Research Oversight Committee; and he is a member of IQVIA's (formerly Quintiles) Ethics Advisory Panel. R.B. sits on the advisory boards of FCDI, Novo Nordisk, LCT, and Oxford Biomedica. I.K. is a Bone Marrow Transplant Physician, vice-President of the Bone Marrow Transplant Society of Australia and New Zealand and a board member of the NSW Stem Cell Network. He actively recruits patients to industry-funded clinical trials but does not receive any honoraria, salary, research, educational, or travel support from industry. G.P. is a member of the board of directors of Holostem Terapie Avanzate, Modena, Italy and consultant of J-TEC, Gamagori, Japan. D.S., T.L., and C.T. have no conflicts to disclose.
Publisher Copyright:
© 2018
PY - 2018/11/13
Y1 - 2018/11/13
N2 - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
AB - Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies. Clinical uses of unproven stem cell-based interventions abound, yet many patients may be harmed by receiving them, raising complex ethical, economic, and societal concerns. Regulators, scientists, clinicians, professional societies, and patient advocacy groups need to collaboratively articulate expectations related to the proper development and delivery of stem cell-based therapies.
UR - http://www.scopus.com/inward/record.url?scp=85055877161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055877161&partnerID=8YFLogxK
U2 - 10.1016/j.stemcr.2018.10.020
DO - 10.1016/j.stemcr.2018.10.020
M3 - Article
C2 - 30428384
AN - SCOPUS:85055877161
VL - 11
SP - 1021
EP - 1025
JO - Stem Cell Reports
JF - Stem Cell Reports
SN - 2213-6711
IS - 5
ER -